FDA D.I.S.C.O.: Two Approvals for ALK-Positive Non-Small Cell Lung Cancer

Media Formats

Ready to Claim Your Credits?

You have attempts to pass this post-test. Take your time and review carefully before submitting.

Good luck!

Details

Comments

Overview
FDA medical oncologists discuss the FDA approvals of brigatinib and ceritinib for ALK-positive non-small cell lung cancer.
Released July 25, 2017

Recommended

Details

Comments

Overview
FDA medical oncologists discuss the FDA approvals of brigatinib and ceritinib for ALK-positive non-small cell lung cancer.
Released July 25, 2017